Literature DB >> 20084406

Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management. Proceedings from a symposium at the 2008 Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting.

Steven Grunberg1, Rebecca A Clark-Snow, Jim Koeller.   

Abstract

INTRODUCTION: Chemotherapy-induced nausea and vomiting remains a significant problem for cancer patients. DISCUSSION: Patient factors such as polypharmacy, medication costs, mucositis, and depression may hinder good antiemetic control, while high workloads, poor communication, and underestimation of the problem on the part of healthcare professionals also play a role. Improving outcomes requires accurate assessment of risk factors, use of guidelines, and better adherence to antiemetic regimens.
CONCLUSION: Extended-release formulations and new delivery systems such as transdermal patches, nasal sprays, and pumps provide a new strategy that may improve patient outcomes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20084406     DOI: 10.1007/s00520-009-0807-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  7 in total

Review 1.  Chemotherapy-induced nausea and vomiting: pathophysiology and therapeutic principles.

Authors:  Juan Bayo; Paula J Fonseca; Susana Hernando; S Servitja; A Calvo; S Falagan; Estefanía García; Iria González; María José de Miguel; Quionia Pérez; Ana Milena; Antonio Ruiz; Agustí Barnadas
Journal:  Clin Transl Oncol       Date:  2012-06       Impact factor: 3.405

2.  Results from the LIDO anemia survey: adherence to EORTC guidelines in cancer patients in France.

Authors:  Vincent Launay-Vacher; Nicolas Janus; Gilbert Deray; Florian Scotté
Journal:  Support Care Cancer       Date:  2016-03-15       Impact factor: 3.603

3.  Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers.

Authors:  Emily S Van Laar; Jayashri Mehta Desai; Aminah Jatoi
Journal:  Support Care Cancer       Date:  2015-01       Impact factor: 3.603

4.  Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy.

Authors:  F Longo; G Mansueto; V Lapadula; L Stumbo; G Del Bene; D Adua; L De Filippis; E Bonizzoni; S Quadrini
Journal:  Int J Clin Pract       Date:  2012-07-02       Impact factor: 2.503

5.  Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens.

Authors:  Sachin Hingmire; Nirmal Raut
Journal:  South Asian J Cancer       Date:  2015 Jan-Mar

6.  The Effect of Foot Reflexology on Chemotherapy-Induced Nausea and Vomiting in Patients With Digestive or Lung Cancer: Randomized Controlled Trial.

Authors:  Audrey Murat-Ringot; Pierre Jean Souquet; Fabien Subtil; Florent Boutitie; Marie Preau; Vincent Piriou
Journal:  JMIR Cancer       Date:  2021-11-05

7.  Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey.

Authors:  Cheryl Vidall; Paz Fernández-Ortega; Diego Cortinovis; Patrick Jahn; Bharat Amlani; Florian Scotté
Journal:  Support Care Cancer       Date:  2015-05-08       Impact factor: 3.603

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.